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risk reduction at discharge (age-adjusted RR 0.68, 95% Cl 0.64-0.72) to 1.2% reduction 
at one year after the MI (age adjusted RR 0.83, 95% Cl 0.79-0.87). These trends were 
magnified among patients with non-Q Ml. Different patient demographics, shorter length 
of stay and higher number of potentially unstable non-Q Ml’s resulting from thrombolysis 
may account for part of the increase in post discharge mortality in 1996. 
Conclusions The increased monality after discharge of MI patients in the thrombolytic era 
diminished the benefit of improved inpatient care. For each 1,000 MI admissions, 38 
more patients were discharged alive in 1996 than in 1986 while one year later only 12 
more were alive. While in-hospital mortality for non-Q MI remained lower (one fourth to 
one third) than that of Cl Ml from 1986 to 1996. the one year mortality for non-Q Ml was 
the same as Q Ml in 1996. 
1126-101 Cytomegalovirus: Strength of Antibody Response and 
Its Relationship to Risk of Mortality Among Patients 
With Angiographic Coronary Disease 
Beniamin D. Home, Joseph B. Muhlestein. John F. Carlquist. Dale G. Renlund. Tami L. 
Bair, Jeffrey L. Anderson, LDS Hospital, Salt Lake City, UT, University of Utah, Salt Lake 
City, UT 
Background: IgG seropositivity to cylomegalovirus (CMV) has been shown in a variety 
of studies to predict future outcome in patients with coronary heart disease (CHD). 
Seropositivity is usually defined by an arbitrary threshold of antibody response. However, 
among CHD patients, whether the strength of antibody response to CMV infection is pra- 
dictive of future outcome is unknown. 
Methods The Registry of the Intermountain Heart Collaborative Study provided a cohort 
of consenting patients (N=2,797) with significant, angiographically-defined atherosclero- 
sis. CMV IgG serology was measured as an immune status ratio (ISR) value by ELISA 
(manufacturer’s criterium for seropositivity is ISR=l.l). Patients were followed for up to 
7.9 years (mean: 3.3r2.0 years) to determine the incidence of all-cause moltality. The 
predictive value for mortality of the continuous distribution of ISR levels was evaluated 
compared to slmpk seropositivity Cox regression adjusted for 24 demographics, CHD 
risk factors, comorbidities, and treatments. 
Results Average age was 65+11 years: 76% were male. A significant linear association 
with mortality was found for the continuous ISR values (hazard ratio (HR]=l.O9/ISR unit, 
p&001). Recursive partitioning confirmed the manufacturer’s threshold for seropositivily 
as an appropriate decision point for CHD risk (seronegative: death=lO%; seropositive: 
death=l9%; fully adjusted Cox: p=O.O16, HR=1.3. 95% CI=l.l-1.7). However, among 
seropositive patients it also revealed a second threshold (ISR=3.76) above which the risk 
of moltality was ameliorated, with death=22% for ISR=l.l-3.76 (n=964, p=O.O38 vs. 
seronagatlve, HR=l.4, Cl=l.O2-1.8) and death=l6% for ISR>3.76 (n=1168, p=O 30 vs. 
seronegative, H&1.2, CI=O.67-1.6). 
Conclusions In this large population of patients with coronary disease at baseline, CMV 
seropositivity was significantly predictive of future mortality. However, the risk was great- 
est for intermediate antibody levels and was ameliorated at higher levels. This raises new 
questions about the nature and complexity of the host immunologic response to CMV 
exposure and how it relates to determination of CHD risk. 
1126-l 02 Is COX-2 Inhibitor Use Associated With an Increased 
Rate of Recurrent Events Among Patients With a Recent 
Cardiovascular Event? 
Roberto A. Corws, Jr, John House, Nancy Drummond, William H. Downham. Steven P. 
Marso, Mid America Heart Institute, Kansas City, MO 
Backaround: Retrospective m&a-analyses have suggested that cyclooxygenase-2 
inhibitor (COX-2) use is associated with an increased risk of thrombotic cardiovascular 
events. 
Methods Patients hospitalized for an initial cardiovascular event (N-2876) were identi- 
fied from a large HMO database usmg specific ICD-9 codes for acute MI, unstable 
angina, or stroke (CVA). Patients with a prior history of cardiovascular or cerebrovascular 
disease were excluded from this analysis. Based on prescription data. patients were sub- 
divided based on active COX-2 use subsequent to the initial cardiovascular event. The 
primary endpoint of this study was the occurrence of cardiovascular mortality, re-infarc- 
tion, CVA, or acute peripheral arterial occlusion wthin one year of the primaly event. 
Regultg There were no significant demographic differences between pabents with 
(N=l70) and without (N=2706) COX-2 use Rates of recurrent cardiovascular events are 
demonstrated below: 
Conclusionr COX-2 use does not confer an increased risk of recurrent events following 
an initial cardiovascular event. Further prospective randomized trials are needed to con- 
firm these findings. 
1126-103 Predicting Early Coronary Revasculariration After an 
Acute Coronary Syndrome 
Jeffrev A. Gavard Bernard R. Chaitman, Shunta Sakai, Karen Stocke, Nicolas Danchin, 
Leif Erhardt. Eric Chi. Andreas Jessel, Richard Gallo, Pierre Theroux, for the GUARDIAN 
Investigators, St. Louis University School of Medicine, St. Louis, MO 
Background: Risk models to predict coronary revascularization (REVASC) within 6 
weeks after an acute coronary syndrome (ACS) may facilitate earlier triage. 
Methods: The GUARDIAN trial contained 4,233 ACS pts without persistent ST elevation. 
Baseline and post-randomization variables were compared between pts with and without 
REVASC. A multivariate logistic regression model was used to develop a REVASC risk 
score. 
Results: REVASC occurred in 1,239 (29.3%) pts. Final multivariate results (table). The 
6-week REVASC risk was 17.6%. 32.8%. and 46.0% for pts with risk scores ~3~4-5. and 
z6, respectively (p<O.OOl); 37.3%, 47.3%, and 15.3% of the pts were in each group. 
Conclusions: Risk scores identify ACS pts at higher risk for REVASC and may assist in 
early triage procedures. 
Univariate Analysis 
With Factor Without Factor 
Risk Factor 
Age ~65 
Male gender 
Multiracial 
N REVASC N REVASC 
(%) (%) 
2.03 32.5 2.19 26.3 
9 4 
2,88 31.8 1.34 23.8 
6 7 
56 48.2 3.92 29.2 
” 
L 
Angina 3,28 31.0 951 23.1 
2 
No CHF 3,65 30.5 582 21.6 
Hypercholesterolem 2,14 33.1 2,08 25.3 
ia 8 5 
Prior PTCA 553 43.2 3.67 27.0 
Serial T wave 1,36 31.7 2.01 24.3 
4 4 
Serial ST elevation 312 44.9 2,Ol 24.3 
4 
Serial Q wave 137 49.6 2,01 24.3 
4 
OR = odds ratio 
Multivariate 
Analysis 
OR ~ p-value 
1.23 co.01 
1.43 co.001 
2.43 co.01 
1.49 <O.OOl 
1.59 <O.OOl 
1.35 <O.cOl 
1.79 ~0.001 
1.50 <O.ool 
2.47 <0.001 
3.22 <O.cOl 
1126-104 Prediction of Two-Year Survival and Composite 
Endpoints Using the TM-7 Risk Score Extended by N- 
Terminal Pro-Brain Natriuretic Peptide Levels 
Rudolf Jarai, Robert Jarai, Ferenc Jarai, Nelly lordanova, Walter S. Speidl. Wolfgang 
Woloszczuk, Georg Geyer, Johann Wojta, Kurt Huber, University of Vienna, Vienna, 
Austria. Ludwig Boltzmann Institute for Experimental Endocrinology, Vienna, Austria 
Background: The TIMI- Risk Score is a useful risk stratification tool for identifvino , - 
patieits with unstable angina. The Brain Natriuretic Peptide (BNP) and the N-terminal 
fraament of it’s orohormone (N-terminal Brain Natriuretic Peotide. NBNP1 are strono. 
“. 
independent predictors of death in patients with acute myocardial infarction and unstable 
coronary disease. However, there exists at present no scoring system for the assess- 
ment of patient’s risk that combines clinical risk scores with one of these natriuretic pep- 
tides. 
Patients and methods: Plasma levels of the NBNP were determined in 145 consecutive 
patients (unstable angina and non-ST-elevation myocardial infarction; UA/NSTEMI) 
admitted to our clinic and were divided into three risk arouos accordina to their TIMI- 
score: high (6-7), medium (4-5) and low risk (l-3). With assistance of the data mining 
techniaue. decision tree (SPSS Inc.. USA). we extended these TIMI Risk orouos with the . 
patients NBNP levels. The so developed combined sconng system consists of 4 groups: 
very high (NBNP>O.G nmol/l), high (TIMI high or TIMI medium risk group and NBNP>0.33 
nmolll), medium (TIMI medium or TIMI low risk group and NBNP>0.33 nmolll) and low 
(TIMI low risk group). 
Results: The relatwe risk of death in the TIMI high, medium and low risk groups was 
30%, 10% and 2%, respectively (p<O.OOl, for trend). If the NBNP level was higher than 
0.33 nmolll (75 percentile) the relative risk of the TIMI groups increased to 44% in the 
high, to 31% in the medium and to 10% in the low risk group. If the NBNP level was 
below this cut-off level, the relative risk of death was 24%, 4% and ~1% in the respective 
TIMI groups. The relative risk of death in the combined TIMI-NBNP groups was 47%, 
20% 4%. and 1%. respectively (p<O.O005, for trend). The receiver operatmg characteris- 
tic (ROC) curve analysis for suwival was performed to test and to compare the predictive 
accuracy of the respective scoring systems. The area under the ROC-curve was 0.77 for 
